These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27422112)

  • 1. Low-Grade Serous Carcinoma of the Ovary.
    Grisham RN
    Oncology (Williston Park); 2016 Jul; 30(7):650-2. PubMed ID: 27422112
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
    Mitchell CL; O'Connor JPB; Jackson A; Parker GJM; Roberts C; Watson Y; Cheung S; Davies K; Buonaccorsi GA; Clamp AR; Hasan J; Byrd L; Backen A; Dive C; Jayson GC
    Ann Oncol; 2010 Oct; 21(10):1982-1989. PubMed ID: 20351070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
    Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
    Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
    Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Grønlund B
    Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H; Pradjatmo H
    Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
    Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
    Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H; Maurer KA; Nutter B; Rose PG
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.
    Fader AN; Java J; Krivak TC; Bristow RE; Tergas AI; Bookman MA; Armstrong DK; Tanner EJ; Gershenson DM
    Gynecol Oncol; 2014 Mar; 132(3):560-5. PubMed ID: 24333362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Origin of ovarian cancer may have implications for screening.
    Tuma RS
    J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic significance of serum CD26 level in Asian women with high-grade serous ovarian carcinoma.
    Shao S; Wang C; Tian J; Zhang H; Wang S; Du Y
    Future Oncol; 2019 Jun; 15(16):1863-1871. PubMed ID: 31140312
    [No Abstract]   [Full Text] [Related]  

  • 18. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
    Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
    Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.